The Balthasar Laboratory is located on the fourth floor of Cooke Hall, on the North Campus of the University at Buffalo. The University at Buffalo is New York State's premier public center for graduate and professional education, as well as the state's largest and most comprehensive public university.

The Balthasar Laboratory utilizes pharmacokinetic and pharmacodynamic modeling and simulation to guide the development of new immunotherapies for the treatment of autoimmunity and cancer.

Current areas of research include:

• Development of new targeting strategies to optimize the safety and efficacy of intraperitoneal chemotherapy of ovarian cancers (CA118213)

• Development of FcRn inhibitors for treatment of humoral autoimmune diseases (e.g., myasthenia gravis, autoimmune neutropenia) (AI60687)

• Development of new strategies to treat immune thrombocytopenic purpura (HL67347)

• Development of improved mathematical models for predicting the disposition and effects of monoclonal antibody drugs

• Investigation of the role of FcRn in the absorption, distribution, and elimination of IgG antibodies

• Investigation of strategies to overcome the "binding site barrier" to antibody distribution in solid tumors